tbuckley/cabot-search huggingface dataset:
Membership of Committees on Education (as of June 30, 1990)
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acromegaly
Authors: Shlomo Melmed
Journal: New England Journal of Medicine (1990)

ACROMEGALY, well described in antiquity, was recognized as a distinct clinical syndrome by Marie in 1886.1 The pituitary source of the disorder was confirmed in 1909 by Cushing, who postulated the excessive secretion of growth-promoting hormone by a hyperfunctioning pituitary gland.2 Recent progress in the diagnosis and treatment of this fascinating clinical syndrome has been reviewed.3 4 5 6 7 Advances in neuroendocrinology have resulted in the development of novel neuropeptide medications that herald a new era of pharmacologic management of hormone-secreting tumors. This review focuses on advances in our understanding of the pathophysiology of acromegaly, diagnosis of the various forms of the disorder, . . .
THE STUDY OF TROPICAL DISEASES.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatitis A and meningoencephalitis
Authors: K. Bromberg
Journal: JAMA (1982)

EXTRAHEPATIC complications of confirmed hepatitis A infection are uncommon and, with the exception of hepatic encephalopathy, have not included CNS involvement.<sup>1-3</sup>Cases of encephalitis presumed to be due to hepatitis A were previously reported before laboratory confirmation of hepatitis A etiology was available.<sup>4,5</sup>The following is a report of a case of serologically confirmed hepatitis A associated with CNS inflammation. <h3>Report of a Case</h3> A previously healthy, 56-year-old businessman was hospitalized in December 1979 with jaundice and decreased mental acuity of several days' duration. Ten days before admission, he experienced fever, sore throat, and cough, with subsequent development of anorexia, mental dullness, confusion, dark urine, and jaundice. Five weeks earlier he had traveled to Europe on a business trip where he had eaten raw seafood. The patient denied excess alcohol intake, toxin exposure, or receipt of blood products. On examination, he was afebrile, icteric, slightly obtunded, and disoriented.
Calcium antagonists and the heart.
Journal: BMJ (1981)

Calcium antagonists and the heartCalcium antagonists are a new class of drugs that are proving very useful in cardiology.An understanding of their action depends on two physiological principles.In all excitable cells, including cardiac muscle, the uneven distribution of electrolytes between the extracellular and intracellular fluids leads to potassium concentrations being higher within the cell and sodium concentrations higher outside.In the resting state the cell membrane is more permeable to potassium than to sodium ions, which are thought to cross membranes through discrete "channels."The action potential at a given membrane site results from sequential changes in membrane ion permeability and the initial depolarisation of the cardiac cell is due to rapid influx of sodium.When this depolarisation has reached a certain level a slow flow of calcium ions prolongs the depolarisation to a "plateau phase"; progressively the membrane becomes more permeable to potassium, less permeable to sodium; repolarisa- tion ensues and the cardiac action potential diminishes.This sequence of events, with slight local modification, occurs throughout the whole conducting system of the heart.Alterna- tion of movements of calcium through the membrane may contribute to many cardiac arrhythmias.1Calcium also plays a fundamental part in the excitation and contraction of both striated and smooth muscle.Muscular
Roentgen Findings in Familial Polyposis with Special Emphasis on Differential Diagnosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health Outcomes of Patients Previously Treated for Lyme Disease
Journal: Annals of Internal Medicine (1999)

Summaries for Patients21 December 1999Health Outcomes of Patients Previously Treated for Lyme DiseaseSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-12-199912210-00024 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Lyme disease is an infection caused by a bacterium carried by ticks. Some people worry that health problems, including arthritis, tiredness, mood disturbances, and memory disturbances, can develop in the years after the infection, even when patients were properly treated with antibiotics. However, few studies have looked to see how often these same problems are found in people without past Lyme disease compared with those who did have the disease.Why did the researchers do this particular study?To find out whether people who had Lyme disease in ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Musculoskeletal and Neurologic Outcomes in Patients with Previously Treated Lyme Disease.” It is in the 12 December 1999 issue of Annals of Internal Medicine (volume 131, pages 919-926). The authors are N.A. Shadick, C.B. Phillips, O. Sangha, E.L. Logigian, R.F. Kaplan, E.A. Wright, A.H. Fossel, K. Fossel, V. Berardi, R.A. Lew, and M.H. Liang.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMusculoskeletal and Neurologic Outcomes in Patients with Previously Treated Lyme Disease Nancy A. Shadick , Charlotte B. Phillips , Oliver Sangha , Eric L. Logigian , Richard F. Kaplan , Elizabeth A. Wright , Anne H. Fossel , Karin Fossel , Victor Berardi , Robert A. Lew , and Matthew H. Liang Metrics 21 December 1999Volume 131, Issue 12Page: 919KeywordsAntibioticsArthralgiaArthritisInfectious diseasesLyme diseaseMemoryMusclesPhysical functioningTicks ePublished: 15 August 2000 Issue Published: 21 December 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.Loading ...
Unexplained lymphadenopathy in homosexual men. A longitudinal study
Authors: D. B. Fishbein
Journal: JAMA (1985)

In January 1982, the Centers for Disease Control began a prospective study of unexplained generalized lymphadenopathy syndrome in 78 homosexual or bisexual men. As of Aug 1, 1984, the median durations of lymphadenopathy and enrollment were 29.5 months and 20 months, respectively. Antibodies to human T-cell lymphotropic virus type III/ lymphadenopathy-associated virus were present in 75 (96%) of the study patients. Five (6%) of the patients were diagnosed as having the acquired immunodeficiency syndrome five to 25 months after the onset of lymphadenopathy. At the time of their initial visit, these five patients had lower T-helper cell counts, hematocrits, lymphocyte counts, and pokeweed mitogen stimulation ratios and were more likely to report severe symptoms than patients who did not develop the acquired immunodeficiency syndrome. During 318 follow-up visits, except for the development of the acquired immunodeficiency syndrome in five patients, there has been little change in the initial laboratory and clinical measures of this cohort. Within the follow-up period of this study, the features of lymphadenopathy syndrome have been unremitting for the majority of patients. (<i>JAMA</i>1985;254:930-935)
In vitro chemosensitivity assay for patients with gynecologic sarcoma.
Authors: A. Santin, J. Varughese, J. Lea
Journal: Journal of Clinical Oncology (2011)

e20513 Background: This study describes the in vitro drug response of tumors from patients with gynecologic sarcoma and explores the clinical implication of in vitro assessment. Methods: Tumors from patients diagnosed with ovarian or uterine sarcoma that were analyzed for response to any of seven drugs (carboplatin [Carb], cisplatin [Cis], paclitaxel [Ptx], docetaxel [Dtx], doxorubicin [Dox], gemcitabine [Gem], ifosfamide [Ifo]) with an in vitro chemosensitivity assay (ChemoFx, Precision Therapeutics, Inc, Pittsburgh PA) from February 1, 2007 to May 3, 2010 were included for analysis. Tumor response was determined from dose response curves. To evaluate combination therapy, tumors were considered sensitive if responsive to at least one of the two drugs. Fisher’s exact test was used to compare group differences. Results: 68 tumors were available for analysis, 21 of which originated in the ovary and 47 in the uterus. 54 of the tumors were primary and 14 recurrent. The most common histologic type was carcinosarcoma (n=53), followed by leiomyosarcoma (n=13), and other (2). 24% of tumors tested were responsive to Carb, 30% to Cis, 33% to Ptx, 9% to Dtx, 18% to Dox, 26% to Gem, 27% to Ifo, 40% to Carb+Ptx, 39% to Cis+Ifo, 48% to Ptx+Ifo, 24% to Gem+Dtx, and 27% to Gem+Dox. The ovarian sarcomas tended to be more responsive in vitro than the uterine sarcomas and the primary more than the recurrent tumors. Carcinosarcomas tended to be more chemoresponsive in general and significantly more responsive than leiomyosarcomas to Ifo (P=0.02). Conclusions: These in vitro chemosensitivity results indicate that ovarian sarcomas tend to be more chemoresponsive than uterine sarcomas and that carcinosarcomas are more chemoresponsive than leiomyosarcomas. Of note, carcinosarcomas were significantly more responsive to Ifo than were leiomyosarcomas. The differential patterns of response observed in these gynecologic sarcomas suggest that in vitro tumor response testing may enable physicians to individualize chemotherapy regimens for their patients.
Levels of Benzo(a)pyrene in Oil Shale Industry Wastes, Some Bodies of Water in the Estonian S.S.R. and in Water Organisms
Authors: I. A. Veldre, A. R. Itra, L. P. Paalme
Journal: Environmental Health Perspectives (1979)

Data on the content of benzo(a)pyrene (BP) in oil shale industry wastewater, the effectiveness of various effluent treatment processes (evaporation, extraction with butyl acetate, trickling filters, aeration tanks) in reducing the level of BP in oil shale wastewater, the level of BP in various bodies of water of Estonia, and in fish and other water organisms are reviewed. The quantitative determination of BP in concentrated diethyl ether extracts of water samples was carried out by ultraviolet and spectroluminescence procedures by use of the quasi-linear spectra at -196 degrees C in solid paraffins. It has been found that oil shale industry wastewater contains large amounts of BP. The most efficient purification process for removing the BP in oil shale industry phenol water is extraction with butyl acetate. The level of BP in the rivers of the oil shale industry area is comparatively higher than in other bodies of water of the Republic. The concentration of BP in the lakes of the Estonian S.S.R. is on the whole insignificant. Even the maximum concentration found in our lakes is as a rule less than the safety limit for BP in bodies of water (0.005 microgram/l). During water is treated at the waterworks. The effectiveness of the water treatment in reducing the level of BP varies from 11 to 88%. Filtration was found to be the most effective treatment. About 20 samples of fish from nine bodies of water in Estonia have been analyzed for content of BP. The average content of BP in the muscular tissue of various species of fish is as a rule less than 1 microgram/kg. There is no significant difference in the concentration of BP in sea and freshwater fish. There is no important difference in the content of BP in the organs of various fish. Fat fish contain more BP than lean ones. The weight (age) of fish does not influence the content of BP in the muscular tissue of fish.
Low-Dose Radioactive Iodine Ablation Is Sufficient in Patients With Small Papillary Thyroid Cancer Having Minor Extrathyroidal Extension and Central Lymph Node Metastasis (T3 N1a): Reply
Authors: Minjung Seo, Yon Seon Kim, Jong Cheol Lee, Myung Woul Han, Eun Sook Kim, Kyung Bin Kim, Seol Hoon Park
Journal: Clinical Nuclear Medicine (2018)

Seo, Minjung MD; Kim, Yon Seon MD; Lee, Jong Cheol MD; Han, Myung Woul MD; Kim, Eun Sook MD; Kim, Kyung Bin MD; Park, Seol Hoon MD Author Information
A community-wide Coxsackievirus A9 outbreak
Authors: A. Novack
Journal: JAMA (1967)

Among members of 33 families, 37% had antibodies to coxsackievirus A9 before, and 93% after, an outbreak of this disease. In all, 88% of the susceptible members of this population converted, serologically. Rash was age related, being more frequent in the very young. Clinical illness was mild but expressed more often in the very young. Among 480 children less than 6 years of age who were bled in well-baby clinics after the epidemic, 58% were found to have coxsackievirus A9 antibodies. Coxsackievirus A9 was the most frequent cause of aseptic meningitis in the community during the epidemic period.
LEUKOCYTOSIS FOLLOWING INTERNAL HEMORRHAGE
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Primer for Diabetic Patients. A Brief Outline of Diabetic Treatment, Including Directions for the Use of Insulin, Sample Menus, Recipes, and Food Tables.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Young Unmarried Mothers in Child Health Stations of Two New York City Districts
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human immunodeficiency viruses and the pathogenesis of AIDS
Authors: J. A. Levy
Journal: JAMA (1989)

THE ACQUIRED immunodeficiency syndrome (AIDS) is caused by a newly recognized member of the lentivirus family, the human immunodeficiency virus (HIV).<sup>1</sup>This retrovirus family is distinct from the other subfamilies of human retroviruses, the<i>Spumavirinae</i>and<i>Oncovirinae</i>(Table 1). In particular, lentivirus genomes are large and contain several viral genes; the viruses frequently induce cytopathic effects in infected cells, and the disease they cause has a long incubation period resulting in immunologic disorders and neurological disease.<sup>2</sup>Lentiviruses have been identified in several other animal species, including horses, sheep, goats, cows, cats, and monkeys.<sup>1,2</sup>This finding suggests that a progenitor virus entered the animal kingdom in the distant past and various strains evolved over time within each species. This could be the reason that the primate and human lentiviruses (the simian immunodeficiency virus and HIV) resemble each other.<sup>3</sup>Two subtypes of HIV, HIV-1 and HIV-2, have been
Treatment of funguria
Authors: A. Wong-Beringer
Journal: JAMA (1992)

We evaluated the use of antifungal agents in the treatment of uncomplicated funguria by reviewing all case reports and studies regarding the treatment of funguria published in the English language from 1960 to 1991 (MEDLINE). Adult patients treated for uncomplicated funguria were included. Patients with fungal pyelonephritis and/or other systemic fungal manifestations were excluded from our analysis. All investigations were assessed for study design, sample size, definition of significant funguria, treatment regimen, inclusion of predisposing risk factors in outcome analysis, end points of therapy, and patient follow-up. Direct comparison of the studies on the use of antifungals in the treatment of uncomplicated funguria was not possible given the differing definitions of significant funguria, inconsistent reporting of risk factors, varying treatment regimens, end points of therapy, and duration of follow-up. Case reports and studies involving antifungals such as amphotericin B bladder irrigation, miconazole nitrate bladder irrigation, ketoconazole, and flucytosine were reviewed. Amphotericin B bladder irrigation appeared to be most effective and ketoconazole the least effective treatment of uncomplicated funguria. Predisposing risk factors, such as the presence of an indwelling urinary catheter, appear to play an important role in the persistence of positive cultures and failure of pharmacologic interventions. Until prospective, well-controlled studies are performed, no recommendation can be made for the treatment of uncomplicated funguria. In symptomatic patients therapy is indicated; however, the best regimen is unknown. (<i>JAMA</i>. 1992;267:2780-2785)